Cytomegalovirus (CMV) infects most people in the world and causes clinically important 28 disease in immune compromised and immune immature individuals. How the virus 29 disseminates from the initial site of infection is poorly understood. We used an innovative 30 approach, involving insertion of target sites for the haematopoietic specific miRNA miR-31 142-3p into an essential viral gene in murine cytomegalovirus. This virus was unable to 32 disseminate to the salivary gland following intranasal infection, demonstrating a strict 33 need for hematopoietic cells for dissemination from the natural site of infection. Viral 34 immune evasion genes that modulate MHC-I expression and NKG2D activation were 35 also required in this setting, as MCMV lacking these genes exhibited impaired 36 dissemination of the viral genome to the salivary gland, and there was no detectable viral 37 replication in the salivary gland. Depletion of T cells rescued the replication of this 38 evasion-deficient virus in the salivary gland. Surprisingly however, the early 39 dissemination to the salivary gland of this evasion-deficient virus, could be rescued by 40 depletion of NK cells, but not T cells. These data are the first to show a profound loss of 41 MCMV fitness in the absence of its MHC-I evasion genes and suggest that they protect 42 the virus from NK cells during hematopoietic dissemination to the salivary gland, where 43 they continued to need the three evasion genes to avoid T cell responses. Remarkably, we 44 found that depletion of NK cells also freed the virus from the need to infect 45 hematopoietic cells in order to reach the salivary gland. Thus, our data show that MCMV 46 adapts to NK cell pressure after intranasal infection by using hematopoietic cells for 47 dissemination while immune evasion genes protect the virus from NK cells during 48 dissemination and from T cells within mucosal tissues. 49 50 Introduction 51
Introduction 51
Cytomegalovirus (CMV), is the most common infectious cause of birth defects in the 52 developed world, leading to hearing loss, vision impairment and cognitive/motor deficits 53 and is estimated to affect 0.5% to 5% of children globally [1] [2] [3] . The greatest risk for the 54 most devastating outcomes of congenital CMV infection occur when a pregnant mother 55 experiences a primary infection and the virus disseminates from the site of entry (most 56 likely the oral/nasal cavity) to the fetus [2, 3] . However, infection of the fetus in this 57 circumstance is not universal. In fact, only ~40% of primary infections during pregnancy 58 result in congenital infection, although the reasons for these drastically different 59 outcomes are unknown. Thus, an understanding of the host/pathogen relationship that 60 governs viral dissemination from the site of entry is critical for the development of 61 effective anti-viral strategies and vaccines. 62
63
Primary CMV infection in immune-competent hosts is usually clinically silent, which 64 makes early natural infection difficult to detect and study. Several excellent animal 65 models have been described for investigating CMV infections, including murine 66
Recent work has shown that the nasal mucosa is a natural site of MCMV entry [4] . Thus, 165
we infected C57BL/6 mice by the intranasal route with either MCMV-IE3-142 or control 166 viruses (either parental wild-type BAC MCMV, or MCMV-IE3-015). All three viruses 167 replicated at the sites of entry (nasal mucosa and lungs). However, two weeks after 168 infection, only control viruses were found to be replicating in the SG ( Figure 1D ). Similar 169 results were obtained after footpad inoculation, which is considered reflective of infection 170 via licking skin abrasions or biting, another possible natural route of infection for MCMV 171 ( Figure 1E ). In contrast, infection by the i.p. route, which allows hematogenous spread of 172 cell-free virus [32] , enabled MCMV-IE3-142 to replicate robustly in the SG ( Figure 1E ). 173
Taken together, these data show that MCMV must utilize infected hematopoietic cells to 174 efficiently spread to SG after intranasal infection 175
176

Evasion of MHC-I antigen-presentation and CD8 + T cells is critical for viral 177
persistence at sites of entry and replication in the salivary gland 178
Since MCMV had to infect hematopoietic cells to spread to SG after i.n. inoculation, we 179 considered whether these infected hematopoietic cells must evade immune control in 180 order to disseminate the virus. MCMV encodes three MHC-I evasion genes (m04, m06 181 and m152), which collectively interfere with the trafficking of mature MHC-I to the cell 182 surface and protect infected cells from killing by CD8 + T cells in vitro [14, 16, [21] [22] [23] [24] . 
CD8
+ T cells ( Figure 2E ). Thus, CD4 + T cell help was critical for the development of 264 functional CD8 + T cell responses after i.n. inoculation, which were able to completely 265 prevent TKO-MCMV from replicating in the salivary gland. 266
267
Early dissemination of TKO-MCMV is restored by NK cell depletion 268
It was possible that MHC-I evasion genes protected MCMV during dissemination to the 269 SG or after it arrived. If MHC-I evasion genes were required during dissemination, we 270 reasoned that we would detect reduced quantities of TKO-MCMV DNA in the SG, which 271 should be rescued by T cell depletion. To specifically assess viral dissemination rather 272 than replication after dissemination, we assessed viral DNA load in the SG 4 days after 273 i.n. inoculation, a time point at which virus-specific CD8 + T cells can be detected in 274 draining lymph nodes, but not yet in the SG ( Figure 3A) . Indeed, the TKO-MCMV DNA 275
load was approximately 10-fold reduced compared to WT-MCMV in unmanipulated 276 
Cell depletions in vivo 542
In some experiments, CD4 + T cells, CD8 + T cells and/or NK cells were depleted 3 days 543 before infection or 7 days after infection. Depletions were conducted by i.p. injection on 544 days 3, 2 and 1 before infection or 7, 8 and 9 days after infection using 0.2 mg of anti-545 mouse CD4 mAb (clone GK1.5), anti-mouse CD8β mAb (clone 53-5.8) and/or anti-546 mouse NK1.1 mAb (clone PK136). Depletions were then maintained for the duration of 547 the experiment by weekly injections with 0.15 mg (GK1.5) or 0.2mg (PK136 and 53-5.8) 548 of antibody. All depleting antibodies were purchased from Bio-x-Cell. Depletions were 549 confirmed by staining for CD4 (clone RM4-4), CD8α (clone 53-6.7) or NKp46 (clone 550
29A1.4). 551 552
Virus titration 553
Nasal mucosa, lungs and salivary glands (SG) were collected at indicated time points post 554 infection and frozen. Nasal mucosa was collected as previously described [40] . Twenty 555 percent homogenates (w/v) were prepared from each collected tissue for virus 556 quantification by plaque assay [40] . Briefly, tissues were weighed and homogenized 557 using a pestle with a small amount of sterile sand in a 1.5 ml centrifuge tube, then 558 suspended with RPMI supplemented with 10% FBS, 100 Units/mL penicillin, and 100 559 µg/mL streptomycin. Supernatants from the homogenate were collected after 560 centrifugation (2400 xg, 10 min) and viral plaque assay was performed on M2-10B4 cells. 561
562
Adoptive transfer of OT-I T cells 563
For adoptive transfer of OT-I T cells we used OT-I transgenic mice expressing CD45.1 as 564 donor cells. Splenocytes containing 5000 OT-I cells from naïve transgenic mice were 565 injected i.v. into sex-matched congenic recipients via the retro-orbital sinus suspended in 566 100 µl PBS. The following day, recipients were i.n. infected with 10 6 PFU MCMV-Ova. 567 568 Lymphocytes isolation, antibodies, tetramer staining, intracellular cytokine 569
stimulation (ICS) and FACS analysis 570
Lymphocytes from the blood were collected from the retro-orbital sinus and mixed with 571 10 µl heparin (1000 units/ml). Lymphocytes from the spleen were collected by 572 homogenization of the spleen through a 70 µM filter and suspended in T cell medium 573 (RPMI-1640 medium with L-glutamine, 10% FBS, 100 units/ml Penicillin, 100 µg/ml 574 Streptomycin, and 5 x 10 -5 M β-mercaptoethanol). CD4 + and CD8 + T cells were identified 575 by antibodies specific for CD3 (clone 17A2), TCRβ (clone H57-597), CD4 (clone RM4-4)and CD8α (clone 53-6.7). OT-I donor cells were further distinguished from recipient 577 cells by CD45.1 (clone A20) and TCR Vα2 (clone B20.1). MHC-I-tetramers loaded with 578 peptides from M45 and M38 were generated at the NIH tetramer core facility 579 (http://tetramer.yerkes.emory.edu/) and used to identify MCMV-specific CD8 + T cells as 580 described previously [75] . For assessment of cytokine production after stimulation, 581 splenocytes were stimulated with 1 µg/ml M38 316-323 peptide (Genemed Synthesis, Inc), 1 582 µg/ml Brefeldin A (GolgiPlug, BD, Bioscience) in the presence of antibody specific for 583 CD107a (clone 1D4B) at 37°C for 3 hours. Cells were chilled on ice, and live cells were 584 discriminated with Zombie Aqua (Biolegend) prior to staining for expression of CD3 585 (clone 17A2), and CD8α (clone 53-6.7). Finally, splenocytes were fixed and 586 permeabilized with Cytofix/Cytoperm (BD Biosciences), following the manufacturer's 587 instructions, and stained for intracellular TNF-α (clone MP6-XT22) and IFN-γ (clone 588 XMG1.2). All antibodies were purchased from Biolegend and cells were collected on BD 589
Fortessa and analyzed with FlowJo sofeware (TreeStar). 590
591
DNA extraction and quantitative real-time PCR (qPCR) 592
For extracting DNA from the SG, 50 µl from a twenty percent homogenate (w/v) was 593 used. For mandibular lymph nodes (manLNs), deep cervical lymph nodes (DCLNs) and 594
